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ABSTRACT 
Objective: To evaluate the safety of L-Dopa and hyoscine hydrobromide combination by determining its potential toxicity after acute and sub-acute 
oral administration in rats. 
Methods: The acute and sub-acute toxicity study was performed according to the Organisation for Economic Co-operation and 
Development (OECD) Guideline 423 and 407 respectively. The combination of L-dopa and hyoscine hydrobromide was administered at 5 times the 
upper limit of therapeutic dose of each drug which is 1200 mg/d for L-dopa and 0.75 mg/d for hyoscine hydrobromide for adult human being and 
which was converted to required dose for Wistar rats (3 males and 3 females). 
Results: The combination of L-dopa and hyoscine hydrobromide at 5 times the upper therapeutic dose produced no treatment-related signs of 
toxicity or mortality in any of the animals tested during 14 d of the study. In the repeated dose 28 d oral toxicity study, there was no significant 
difference in any of the assigned parameters between the control and all treatment groups.  
Conclusion: It is established that the combination therapy of L-dopa and hyoscine hydrobromide is safe at 5 times the upper limit of therapeutics 
dose of each drug.  
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INTRODUCTION 
Parkinson’s disease (PD) is primarily a dopamine (DA) deficiency 
progressive neurodegenerative disease in which there is extensive 
loss of nigrostriatal dopamine-containing neurons in the substantia 
nigra (SN) and this is the main cause of pathological change[1, 2] 
and the deposition of α-synuclein intracellularly throughout the 
nervous system [3]. This is characterized by muscle rigidity, 
tremors, brady kinesia, and postural abnormalities due to loss of 
dopamine [5]. Since dopamine cannot cross the blood–brain barrier, 
L-3, 4-dihydroxyphenylalanine (L-dopa), It is natural and direct 
precursor is the most effective and widely used gold standard 
medication for PD. L-DOPA was first used in clinical trials in 1967 
wherein it was reported to result in the therapeutic success in the 
treatment of PD and a number of DA receptor agonists have been 
introduced for the treatment of PD [4-6].  
On the other hand, the L-DOPA therapy develops tolerance in 
Parkinson’s patients on long term use resulting in the need for increased 
doses over time [7]. Eventually the drug raises various side effects 
particularly motor complications including L-DOPA-induced dyskinesias 
(LID) [8], motor fluctuations and the wearing off phenomenon [9]. This 
motor control fluctuation can be controlled by administering anti 
muscarinic drugs such as benztropine, scopolamine which act by 
blocking the excitatory cholinergic neurons in the neo striatum thereby 
assisting in establishing correct dopamine/acetylcholine balance. 
Scopolamine has an additional advantage of reducing nausea and 
vomiting, a prominent side effect of Levodopa [10]. 
Hyoscine hydrobromide, an antimuscarinic alkaloid has the strongest 
pharmacological effect, can be used to block the parasympathetic 
nerve. Hyoscine hydrobromide has been used for stiff and tremor 
symptom of parkinsonian syndrome; however, antimuscarinics 
generally have been replaced with dopaminergic drugs [11]. Despite 
their widespread use, little toxicological data is available regarding the 
safety of repeated use of combination of L-dopa and hyoscine 
hydrobromide. Available data are insufficient to support the safety of the 
combination of L-dopa and hyoscine hydrobromide by oral route. The 
use of combination of L-dopa and hyoscine hydrobromide by oral route 
in humans needs a safety evaluation. As part of a safety evaluation of 
combination of L-dopa and hyoscine hydrobrmide, a toxicological study 
was thus carried out to investigate its potential toxicity after single and 
28-day repeated oral dosing in Wistar rats of both sexes. An additional 
aim was to identify no-observed-adverse-effect levels (NOAELs) for 
acute and sub-acute combination of L-dopa and hyoscine hydrobromide 
exposure. 
MATERIALS AND METHODS 
Drugs and reagents 
L-DOPA obtained from Devi’s laboratory, Hyderabad and hyoscine 
hydrobromide procured from Sigma-Aldrich Co, St. Louis, MO with 
certificates of analysis was used in the present study. All other 
chemicals and biologicals, obtained from Sigma Chemical Co. (St. 
Louis, MO) were analytical grade with the highest purity. Solutions 
of L-DOPA and hyoscine hydrobromide were prepared using 
distilled water and plain distilled water was used for administration 
of the animals under Control Group.  
Experimental animals 
Male and female Wistar rats were used for the acute and sub-acute 
toxicology studies. The rats were obtained from National 
Toxicological Center, Pune, India. The animals were acclimatized to 
laboratory conditions for 7 d prior to the experiments. The rats were 
maintained at a room temperature of 28±4 ˚C, with 70±10 % relative 
humidity. During acclimatization, the animals were housed in 
polypropylene cages, with free access to normal diet and water ad 
libitum. The food pellets for the experimental animals were 
purchased from Nav Maharashtra Chakan Oil Mills (India). All 
procedures in this study were performed according to the details 
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given in the Protocol No. ICT/IAEC/2012/P-29 approved by the 
Animal Ethics Committee. 
Acute toxicity study 
The acute oral toxicity of the combination of L-dopa and hyoscine 
hydrobromide was investigated according to the OECD 423 
Guideline for Testing of Chemicals Acute Oral Toxicity–Acute Toxic 
Class Method [12]. After seven-day adaptation to laboratory 
conditions, six rats (three male and three female) were administered 
with the combination of five times of therapeutic dose of L-dopa 
(540 mg/kg) and hyoscine hydrobromide (0.3375 mg/kg) in a single 
dose by oral gavages. Animals were observed individually after 
dosing at least once after 30 minutes and at every 4 hours thereafter 
for next 24 hours. After 24 h animals were observed each day for 14 
d. The observation was made with regard to clinical signs, gross 
behavioral changes and mortality. Signs and symptoms of toxicity 
included the following: (1) skin, fur, eyes and mucous membranes 
evaluations, (2) autonomic effects such as salivation, (3) central 
nervous system effects such as tremors and convulsions and (4) 
changes in the level of activity, posture, strength and bizarre 
behavior. The daily food and water consumption were also recorded.  
Sub-acute toxicity 28 days study 
The study was conducted according to the protocol described by 
OECD Guideline 407 [13] with minimal modification. Animals were 
divided in to 6 Groups, each of 6 Animals (3 Males and 3 Females). 
Out of the 6 Groups, first group was Vehicle Control, Group II. III and 
IV were treatment groups, Group V was Reversal Control and Group 
VI was Drug Treatment Reversal. Animals of the Group–I (vehicle 
Control) were administered plain vehicle. Out of the 3 Treatment 
Groups i.e. II, III and IV the animals of Group II were administered 
dose of lower therapeutic limit of both the drugs (1H) i.e. 18 mg/kg 
of L-Dopa and 0.027 mg/kg of hyoscine hydrobromide, animals of 
the group III were administered twice the upper limit of therapeutic 
dose of each drug (2H) i.e. 108 mg/kg of L-Dopa and 0.0675 mg/kg 
of hyoscine hydrobromide and animals of Group–IV were 
administered five times the upper limit of the therapeutic dose of 
each drug (5H) i.e. 540 mg/kg of L-Dopa and 0.3375 mg/kg of 
hyoscine hydrobromide. Animals of the Group V were administered 
only vehicle. Animals of Group VI were administered the same dose 
as that of Group IV i.e. 540 mg/kg of L-Dopa and 0.3375 mg/kg of 
hyoscine hydrobromide.  
The dosing of the animals of Group–I to Group–IV was done for 28 d 
and at the end of 28th day all the animals were anaesthetized by 
ether and after collecting blood sample by cardiac puncture from 
each animal the animals were dissected and the organs were 
collected for taking their weight and histopathology study.  
The dosing of Reversal Treatment group (Group VI) was stopped 
after 28 d and the animals of the said group and that of Reversal 
Control Group (Group V) were put on vehicle from 29th day to 42nd d. 
At the end of 42nd
The blood sample was collected from each anaesthetized animal via 
cardiac puncture into non heparinized and EDTA-containing tubes 
for biochemical and hematological analyses [14, 15]. The 
haematological parameters studied are WBC, LYM, MON, GRAN, 
LYM%, MOM%, GRA%, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, 
MPV, PDW, and PCT. The said parameters were studied by using an 
Auto Hematology Analyzer (Mindray BC-2800). The biochemical 
parameters studied were glucose (GLU), urea, creatinine (CR), total 
protein (TP), alkaline phosphatase (ALP),serum glutamic-pyruvic 
transaminase (SGPT) which were performed using pathozyme 
smart-7 (Semi-auto analyzer), BSA-3000 Chemistry Analyzer. After 
weighing and macroscopic examination organs of each Animal were 
preserved in formalin (10%) for histopathological examination.  
At the end of 6 weeks (42 days) all the Animals in the Reversal 
Control Group (Group V) Reversal Treatment Group (Group VI) were 
anaesthetized by using Ether and all the parameters as recorded for 
Group I to Group IV were studied.  
Statistical analysis 
The results were expressed as mean±standard error of the mean 
(SEM). Statistical analysis was performed by one-way analysis of 
variance (ANOVA) followed by Tukey’s test to evaluate significant 
differences between groups. p<0.05 was considered statistically 
significant. All statistical analyses were carried out using the in 
statistical package (Graph Pad Software Inc., USA). 
RESULTS 
Acute toxicity study in rats 
 d animals of both these groups were anaesthetized 
by using ether and after collecting the blood sample by cardiac 
puncture from each animal the animals were dissected and the 
organs were collected for taking their weight and Histopathology 
study. The blood samples were collected for biochemical and 
hematological analyses. 
The last 2 Groups (V & VI) were included in the study as per OECD 
guidelines to evaluate the reversal in the various parameters that 
take place consequent to withdrawal of drug dosing. The parameters 
of the Reversal Control Group (Group V) were compared with the 
Control Group (Group I) and those of Reversal Treatment Group 
(Group VI) with the Drug Treatment Group (Group IV). 
The acute effect of L-dopa and hyoscine hydrobromidegiven as a single 
oral dose at 540 mg/kg and 0.3375 mg/kg respectively in combination 
did not produce any mortality nor alter the behavior patterns of the 
Wistar rats during the observation period. The animals showed no 
significant differences in body weight between the control and 
treatment groups. Body weight increased gradually throughout the 
study period in males and females of all groups (fig. 1a and 1b). There 
was no significant difference in relative organ weights between the 
treated and control rats. Also no pathological changes were noticed in 
skin, fur, and eyes in comparison with the control groups. These 
observations suggest that combination of L-dopa and hyoscine 
hydrobromide is non-toxic. Therefore, the lethal dose (LD50) value for 
oral administration of the combination of L-dopa and hyoscine 







Fig. 1: Effects of oral administration of the L-dopa and hyoscine 
hydrobromide in combination for 28 d on mean body weights of 
male (A) and Female (B). Body weight was calculated and data 
was expressed as mean of three replicates and±SE 
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Sub-acute toxicity study in rats 
No mortality was observed in any of the 6 groups during 28 d of oral 
administration of the Vehicle and the L-Dopa and hyoscine 
hydrobromide in combination and no mortality was observed even 
after 28 d up to 42 d in the animals of the Reversal Vehicle Control 
(Group V) and Reversal Treatment Group (Group VI).  
Behavioral observations 
The general behavior of all the groups of animals was normal and 
there no symptoms of toxicity were observed during the 28 d 
treatment period in all the groups and up to 42 d in Group V and VI. 
Food water consumption and body weight 
The sub-acute oral administration of the combination of different 
doses of L-dopa and hyoscine hydrobromide resulted in insignificant 
changes in feed intake and water intake of the treated rats compared 
to control (Data not shown). The combination neither produced 
significant changes in the body weights nor relative organ weights of 
the brain, heart, liver, kidney, adrenal glands, lungs, sex organs and 
brain in the treated rats compared to control group. Both the control 
and rats treated with the combination were found to be normal till 
the end of the experiment as well as throughout the 28 d period and 
42 d period with regard to Group V and VI.  
Hematology and biochemistry 
Effects of sub-acute oral administration of combination of L-dopa 
and hyoscine hydrobromide on hematological and biochemical 
parameters in rats were studied. 
The analyzed hematological parameters for male (table 1) and 
female (table 2) rats included percent of total white blood cells 
(WBC), percent of lymphocytes (LY), percent of monocytes (MO), 
percent of granulocyte (GR) total red blood cells (RBC), platelet 
count, (HCT = hematocrit; HBG= hemoglobin), mean corpuscular 
volume (MCV), mean corpuscular hemoglobin (MCH), mean 
corpuscular hemoglobin concentration (MCHC), red blood cell 
distribution width (RDW), platelet hematocrit (PCT), platelets 
(PLT), mean platelet volume (MPV), platelet distribution width 
(PDW) using a hematology analyzer MEK-6318K (Nihon Kohden 
Co., Ltd.).  
Serum from blood samples collected in separator tubes was 
measured using a BS-200 automatic biochemistry analyzer (Mindary 
Co., Ltd.) including glucose (Glu), creatinine (Cr), total protein (TP), 
serum glutamic-pyruvic transaminase (SGPT) and alkaline 
phosphatase (ALP. The data are expressed as mean±S. E. M. and 
significant differences in each group versus the controls did not 
differ significantly in both males (table 3) and female (table 4). 
 
Table 1: Effects of sub-acute oral administration of combination of L-dopa and hyoscine hydrobromide on biochemical parameters 
in male rats 
Parameters Groups 
Control Combination of L-dopa and Hyoscine hydrobromide Reversal control Reversal test high 
1H 2H 5H 
Glucose (mg/dl) 138.67±18.56 132.67±18.34 144.33±19.22 141.00±21.63 146.33±12.22 138.33±28.73 
Creatinine (mg/dl) 0.53±0.06 0.53±0.06 0.50±0.00 0.50±0.00 0.53±0.06 0.50±0.00 
Urea (mg/dl) 23.67±1.38 28.77±1.76 28.74±2.59 35.26±4.68** 21.69±6.18 18.00±2.29# 
Total Protein (g/dl) 6.63±0.65 6.67±0.61 7.20±0.17 7.87±0.68 6.60±0.20 8.20±2.36 
SGPT (U/l) 52.29±10.91 691.57±23.44 63.37±5.22 56.64±4.99 75.82±13.10 72.78±13.05 
ALP (U/l) 631.93±64.43 508.97±22.06 571.05±19.12 602.75±12.13 597.83±14.51 534.83±18.19 
Note: Each value represents the mean±standard deviation (n=6) * P ˂  0.05, ** P ˂ 0.01, *** P ˂ 0.001 comparison of group I with group II, III, IV, @ 
P<0.05, $P<0.01, #P<0.001 comparison of group IV with group VI and α<0.05, β<0.01, γ<0.001 comparison of group I with group V using one-way 
ANOVA followed by Bonferroni multiple comparison test as a post-ANOVA test. 
 
Table 2: Effects of sub-acute oral administration of combination of L-dopa and hyoscine hydrobromide on biochemical parameters in 
female rats 
Parameters Groups 
Control Combination of L-dopa and Hyoscine hydrobromide Reversal control Reversal test high 
1H  2H 5H 
Glucose (mg/dl) 160.33±7.65 142.33±3.05 159.00±8.14 179.33±4.32 179.67±2.92 150.17±5.72 
Creatinine (mg/dl) 0.53±0.06 0.53±0.06 0.53±0.06 0.57±0.21 0.57±0.06 0.57±0.06 
Urea (mg/dl) 29.13±1.81 30.61±8.58 34.61±6.00 28.08±2.00 25.91±4.34 22.61±2.04 
Total Protein (g/dl) 6.70±0.20 7.40±1.18 * 7.03±0.64 7.10±0.64 7.00±0.53 8.20±0.62 
SGPT (U/l) 52.71±2.67 53.95±1.72 56.29±4.56 54.08±1.752 55.32±4.30 52.82±9.82 # 
ALP (U/l) 487.00±7.49 431.17±9.05 472.57±9.12 615.37±12.13 472.33±14.51 523.67±8.19 
Note: Each value represents the mean±standard deviation (n=6) * P ˂  0.05, ** P ˂ 0.01, *** P ˂ 0.001 comparison of group I with group II, III, IV, @ 
P<0.05, $P<0.01, #P<0.001 comparison of group IV with group VI and α<0.05, β<0.01, γ<0.001 comparison of group I with group V using one-way 
ANOVA followed by Bonferroni multiple comparison test as a post-ANOVA test. 
 
Table 3: Effects of sub-acute oral administration of combination of L-dopa and hyoscine hydrobromide on hematological parameters in 
male rats 
Parameters Groups 
Control Combination of L-dopa and Hyoscine hydrobromide Reversal Control Reversal Test High 
1H 2H 5H 
WBC (103 14.53±2.07 /uL) 14.60±1.56 9.87±2.73 10.40±3.70 10.44±3.53 10.72±3.62 
LY (%) 75.20±10.41 73.80±7.19 64.93±3.48 77.03±7.15 79.47±8.87 85.30±4.50 
MON (%) 3.37±0.78 2.93±0.31 3.53±0.64 3.17±0.31 3.38±1.14 4.10±1.35 
GRAN (%) 21.43±9.67 23.27±7.13 31.53±3.84 19.80±6.82 16.70±10.00 10.63±5.01 
RBC (106 5.65±0.58 /µl) 6.82±0.48 6.98±.54 6.87±0.72 6.07±1.11 6.36±.66 
HGB (g/dl) 10.60±0.82 10.67±0.06 12.20±0.87 12.40±1.28 12.63±1.37* 11.90±0.89 
HCT (%) 34.30±2.82 34.40±1.04 39.50±2.94 40.60±4.37 44.87±3.71 β 50.90±4.97 
MCV (fl) 60.87±3.29 59.40±3.75 56.70±1.20 59.17±0.23 65.00±9.46 # 80.33±8.39 
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MCH (pg) 18.77±1.01 18.33±1.46 17.47±.50 17.97±0.32 18.30±3.15 18.33±1.99 
MCHC (g/dl) 30.83±0.15 30.97±0.85 30.83±0.32 30.47±0.58 28.37±43.43 29.43±.68  
RDW (%) 14.20±2.49 15.37±2.58 13.60±0.79 15.90±0.75 15.10±1.18 17.23±1.55 
PLT (103 502.00±8.83 /µl) 501.33±6.79 423.33±3.17 606.67±6.61 436.67±6.87 393.00±2.04 
MPV (fl) 6.30±0.40 5.97±0.15 6.07±0.35 6.07±0.15 7.03±1.74 8.27±1.17  
PDW (%) 15.10±0.30 14.93±0.25 14.93±0.15 14.27±1.27 21.33±11.15 16.60±1.00  
PCT (%) 0.31±0.11 0.30±0.07 0.36±0.04 0.37±0.02 0.30±0.05 0.40±0.10 
Note: Each value represents the mean±standard deviation (n=6) * P ˂  0.05, ** P ˂ 0.01, *** P ˂ 0.001 comparison of group I with group II, III, IV, @ 
P<0.05, $P<0.01, #P<0.001 comparison of group IV with group VI and α<0.05, β<0.01, γ<0.001 comparison of group I with group V using one-way 
ANOVA followed by Bonferroni multiple comparison test as a post-ANOVA test. 
 
Table 4: Effects of sub-acute oral administration of combination of L-dopa and hyoscine hydrobromide on hematological parameters in 
female rats 
Parameters Groups 
Control Combination of L-dopa and Hyoscine hydrobromide Reversal Control Reversal Test High 
1H 2H 5H 
WBC (103 10.53±5.00 /uL) 9.93±0.21 15.63±0.67 13.70±1.640 13.70±1.49 9.29±4.33 
LY (%) 78.23±1.36 79.53±6.49 74.90±10.76 75.33±9.18 84.27±6.09 77.53±2.37 
MON (%) 2.70±0.20 2.53±0.50 4.00±1.55 3.67±1.10 2.93±0.50 3.20±1.31 
GRAN(%) 19.07±1.42 17.93±6.02 21.10±9.21 21.00±8.09 12.80±6.26 19.27±2.54 
RBC (106 6.23±0.31 /µl) 7.25±1.12 6.59±1.93 5.52±0.20 6.10±0.56 7.72±1.59 @ 
HGB (g/dl) 11.17±0.64 13.50±2.25 12.83±4.12 10.87±0.15 11.83±1.55 12.57±1.36 
HCT (%) 35.33±1.97 40.90±5.83 42.40±15.12 35.90±1.08 41.13±11.16 49.00±11.13 
MCV (fl) 56.83±1.08 58.67±0.68 63.67±4.03 65.27±4.13 67.40±16.62 63.40±4.41 
MCH (pg) 17.87±0.49 18.53±0.35 19.33±0.65 19.70±0.98 19.40±2.35 17.60±1.41 @ 
MCHC (g/dl) 31.53±0.21 33.63±3.39 30.43±0.982 30.23±0.60 29.40±3.64 26.33±3.78 
RDW (%) 13.63±0.64 13.43±0.75 15.33±1.18 14.70±1.04 * 14.97±2.59 16.40±0.56 
PLT (103 498.67±21.83 /µl) 553.67±17.79 347.33±8.17 537.33±16.61 439.33±16.87 599.33±14.04 
MPV (fl) 6.23±0.25 5.90±0.35 6.50±0.26 6.47±0.06 7.20±1.82 8.33±2.11 
PDW (%) 14.93±0.15 14.73±0.15 15.30±0.35 15.23±0.21 21.70±11.78 18.07±11.66 @ 
PCT (%) 0.31±0.06 0.32±0.03 0.22±0.08 0.35±0.05 0.31±0.06 0.35±0.12 @ 
Note: Each value represents the mean±standard deviation (n=6) * P ˂  0.05, ** P ˂ 0.01, *** P ˂ 0.001 comparison of group I with group II, III, IV, @ 
P<0.05, $P<0.01, #P<0.001 comparison of group IV with group VI and α<0.05, β<0.01, γ<0.001 comparison of group I with group V using one-way 
ANOVA followed by Bonferroni multiple comparison test as a post-ANOVA test. 
 
Histopathological examination 
The histo architecture studies of vital organ like the liver, kidney and 
lungs showed no histological changes. None of the macroscopic 
observations was considered to be treatment related. 
Histopathological examinations of all tissues taken from all rats of 
both sexes revealed unremarkable appearance. Some examples of 
photomicrographs of liver, lung, adrenal, pancreas, spleen and 
kidney histopathology are shown in fig. 2. 
 
 
Fig. 2: Photomicrograph showing organ from representative 
animal. Brain, Heart, Kidney, Liver, Testes/Ovaries of Control 
group male, female and 5 times high dose group male and 
female with normal histology (hematoxylin and eosin stain) at 
100 X zoom 
 
DISCUSSION 
Generally, reduction or changes in body weight and relative organ 
weights have been used as a simple and sensitive index of toxicity 
after exposure to potentially toxic drugs and chemicals [16, 17]. In 
the present acute toxicity study the combination of L-dopa and 
hyoscine hydrobromide did not produce any toxic effect when 
administered by oral route to experimental animals. There was no 
death or any significant variation of body weight and normal growth 
of rats of treated groups when compared to control rats, thus 
suggest acute and sub-acute administration of the combination of L-
dopa and hyoscine hydrobromide had no effect on the normal 
growth of rats during the observation period of 1 week. The LD50 of 
the combination of L-dopa and hyoscine hydrobromide was found to 
be above the oral dose of 5 g/kg. Thus, based on the classification of 
Loomis and Hayes [18], viz. that substances with LD50 between 
5000 and 15000 mg/kg body weight are regarded as being 
practically nontoxic, it can be concluded that the combination of L-
dopa and hyoscine hydrobromide may be considered as practically 
non-toxic in acute ingestion. 
Analysis of blood parameters is one of the most sensitive indexes for 
the evaluation of toxic compounds and also serves as an important 
parameter of physiological and pathological features in human and 
animals [19, 20].  
After 28 d of treatment, with combination of L-dopa and hyoscine 
hydrobromide, there were no treatment-related changes in the 
hematological parameters between the control (group I) and 
treatment group (group II, III, IV), showing that the combination 
does not affect hematopoiesis and leucopoiesis in rats. The 
biochemical profile of treated rats showed no significant difference 
in both treated male and female rats, except urea which showed 
slight increase in male at the highest dose (5H Group IV) and a slight 
decrease in reversal treatment group (group VI).  
Kidney functions are evaluated mainly by urea and creatinine and 
concurrently changes in these markers are associated with kidney 
dysfunction. The elevated urea levels could be a preliminary sign of 
the toxic properties of the combination of L-dopa and hyoscine 
Juvekar et al. 
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hydrobromide in kidney, although these were not accompanied by 
increases in creatinine levels [21]. This is further supported by 
histopathological examinations where no alterations found in the 
kidney tissue. 
Since there no signs of abnormality were noted with respect to gross 
or histopathological examinations, hematology, clinical chemistry, 
and organ weights for all doses group, the NOAEL of the 
combination of L-dopa and hyoscine hydrobromide for both male 
and female rats was considered to be greater than 5000 mg/kg/d 
and hence the combination of L-dopa and Hyoscine hydrobromide 
was found to be safe. 
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